Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program | Synapse
March 3, 2026Open Access
Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program
Key Points
Treatment burden decreases significantly with insulin efsitora alfa compared to the daily comparator, enhancing patient satisfaction.
In QWINT trials, 80% of adults reported improved overall health state when using efsitora alfa versus other insulin.
Assessment included qualitative measures of treatment satisfaction over a six-month period among adults with type 2 diabetes.
Improving satisfaction with efsitora alfa may lead to better adherence to diabetic management strategies.